During my studies of Nutritional Sciences (B.Sc.) I was especially intrigued by the molecular pathways involved in metabolic disease progression. Therefore, I studied Molecular Medicine for my master’s (M.Sc.) and realized that I want to specifically focus on the investigation of metabolic diseases. In 2015, I started my PhD at the Helmholtz Center Munich, the Institute for Diabetes and Obesity in the division of Molecular Pharmacology. I assessed the role of a cold and nicotine receptor in the regulation of whole-body energy metabolism under the supervision of Prof. Matthias Tschöp. By pharmacologically mimicking cold exposure and simultaneously activating α3β4 nicotinic acetylcholine receptors, we could synergistically reduce body weight, restore a healthy glucose metabolism, and reverse non-alcoholic fatty liver disease in mice fed a high-fat diet.
I finished my PhD in 2019 and look forward to learning elaborate techniques in the lab of Prof. David James, such as mass-spectrometry based proteomics, which enable us to further parse out the molecular dysregulations that contribute to the progression of insulin resistance and type 2 diabetes.
Contact: sigrid.jall (at) sydney.edu.au